I. Mikačić

An unmet medical need vs. regulatory recommendations: how should we treat patients with hyperaldosteronism and advanced chronic kidney disease when surgery is not feasible?

I. Mikačić, 2019, European Journal of Clinical Pharmacology.

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Eddie B. S. Tan, Nishit P. Parikh, Rajan K. Patel, 2023, The Lancet.

Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies

D. Bosnar, I. Mikačić, 2016, Drug Safety.

A Proximity Extension Assay (PEA)-based method for quantification of bevacizumab.

O. Vugrek, R. Beluzic, I. Mikačić, 2018, Journal of pharmacological and toxicological methods.

From Head to Toe: When Limited Cutaneous Scleroderma Becomes Serious and Severe.

I. Mikačić, Karolina Majstorović Barać, Đuro Plavljanić, 2019, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.